甲磺酸伊马替尼治疗慢性粒细胞白血病的临床疗效评价

Clinical Efficacy Evaluation of Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia

目的探讨甲磺酸伊马替尼治疗慢性粒细胞白血病的临床疗效。方法选取我院2015年1月—2017年1月收治的84例慢性粒细胞白血病患者进行回顾性分析,根据不同治疗方法的分为两组,对照组(n=42)给予常规化疗,观察组(n=42)在对照组基础上给予甲磺酸伊马替尼治疗,对比两组患者临床疗效和不良反应发生率。结果观察组和对照组患者临床疗效分别为76.19%和50.00%,差异有统计学意义(P <0.05)。两组患者不良反应发生率分别为11.90%和38.10%,差异有统计学意义(P <0.05)。结论甲磺酸伊马替尼治疗慢性粒细胞白血病,不仅具有显著的效果,还具有较高的安全性。

Objective To investigate the clinical efficacy of imatinib mesylate in the treatment of chronic myeloid leukemia.Methods 84 patients with chronic myelogenous leukemia admitted to our hospital from January 2015 to January 2017 were divided into two groups according to different treatment methods.The control group(n=42)was given conventional chemotherapy,and the observation group(n=42)was given imatinib mesylate on the basis of the control group.The clinical efficacy and adverse effects of the two groups were compared.Results The clinical efficacy of the two groups was 76.19%and 50.00%respectively,with significant difference(P<0.05).The incidence of adverse reactions was 11.90%and 38.10%respectively,with significant difference(P<0.05).Conclusion Imatinib mesylate not only has significant effect,but also has high safety in the treatment of chronic myeloid leukemia.